Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 600 first isolates · SURG · Skin / wound infection · 2023-12-24 → 2024-12-22
SurgeryNo single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 53 % (49 %–57 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (98 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious
diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (16 %), Escherichia coli (13 %), Proteus mirabilis (7 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
mecillinam MEC
not for this site0 %
0 %
n = 43
trimethoprim TMP
not for this site0 %
0 %
n = 43
nitrofurantoin NIT
not for this site0 %
0 %
n = 43
Most likely organisms for this profile
Staphylococcus aureus
44 %
Pseudomonas aeruginosa
16 %
Escherichia coli
13 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Klebsiella pneumoniae
6 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.